Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AUTL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
AUTL reported $201.6M in cash and short-term investments (as of Jun 30, 2026) and used about $45.6M/quarter in operations, an estimated runway of 13.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 33 · Moderate
Accordingly, management has concluded that there are no conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AUTL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| MAK Capital Fund LP | 5%+ holder (13G) | 33,621,487 | 12.63% | 2026-03-31 |
| Armistice Capital, LLC | Institution (13G, 5%+) | 15,000,000 | 5.64% | 2026-06-30 |
| Renata Kellnerova | 5%+ holder (13D) | 14,782,275 | 5.55% | 2026-08-27 |
Share count 266,162,540 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AUTL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →